Biodegradable Poly(Acetonide Gluconic Acid) for Controlled Drug Delivery.

We report here on the synthesis, characterization, degradation, and drug release of acetal-protected gluconic acid-based poly(α-hydroxy ester). This polyester was synthesized by ring-opening polymerization of O-carboxyanhydride of acetal-protected gluconic acid. The polymer undergoes hydrolytic degradation under mild acidic media, whereas minimal degradation takes place under physiological pH. Under acidic conditions, the acetal-protecting groups are hydrolyzed, resulting in a water-soluble polyester with saccharide side chains that erodes from the surface, leaving the bulk of the polymer matrix intact. At pH 3.5, zero-order kinetics was maintained for 50 days accounting for ∼75% drug release. These biodegradable, pH-responsive, sustained zero-order release kinetics of the polymer have application as drug carriers for oral drug delivery or medical implants or also for nonmedical applications.

Novel acylethanolamide derivatives that modulate body weight through enhancement of hypothalamic pro-opiomelanocortin (POMC) and/or decreased neuropeptide Y (NPY).

Newly synthesized acylethanolamide derivatives oleoyl-L-valinolamide (1), oleoyl-D-valinolamide (2), elaidoyl-L-valinolamide (3), elaidoyl-D-valinolamide (4) stearoyl-L-valinolamide (5), and palmitoyl-L-valinolamide (6) were investigated in mice as antiobesity compounds. Compounds 1, 2, 5, 6 significantly decreased body weight by 6.57% following eight injections of 1 mg/kg i.p. during 39 days, while 3 and 4 showed no such activity. Receptor binding indicated that no compound activated CB1, CB2, PPARα, or TRPV1 receptors. Hypothalamic RT-PCR showed that mRNA expression of the anorexigenic genes POMC and CART was up-regulated by 1, 2, 5 and 1, 2, respectively, while that of the orexigenic genes NPY and CaMKK2 was down-regulated by the respective compounds 1, 5, 6 and 1, 2, 5. Oleoyl-L-valinolamide enhances anorectic pathways and lead to decreased glucose levels, enhanced locomotor activity, and improved cognition. Effects of oleoyl-L-valinolamide on weight were dose-dependent, and it could be given orally. 1, 2, 4, 5 down-regulated FAAH mRNA expression.